PDE5 Inhibitors and their Applications

被引：23

作者：

Giovannoni, M. P. ^{[1
]}

Vergelli, C. ^{[1
]}

Graziano, A. ^{[1
]}

Dal Piaz, V. ^{[1
]}

机构：

[1] Univ Firenze, Dipartimento Sci Farmaceut, I-50019 Florence, Italy

来源：

CURRENT MEDICINAL CHEMISTRY | 2010年 / 17卷 / 24期

关键词：

Phosphodiesterase 5 (PDE5); selectivity; therapeutic applications; PHOSPHODIESTERASE TYPE-5 INHIBITOR; URINARY-TRACT SYMPTOMS; HUMAN CGMP-BINDING; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BENIGN PROSTATIC HYPERPLASIA; OBJECT RECOGNITION MEMORY; FEMALE SEXUAL DYSFUNCTION; MALE ERECTILE DYSFUNCTION; DEPENDENT PROTEIN-KINASE; POTENTIAL AGENTS;

D O I：

10.2174/092986710791859360

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

PDE5 belongs to a superfamily of enzymes that catalyzes the hydrolysis of cyclic nucleotides cAMP and cGMP to the corresponding 5-nucleoside monophosphate. PDE5 takes part in many physiological and pathological functions, therefore selective PDE5 inhibitors are potentially useful for a variety of pathologies. At the present, PDE5 inhibitors available on the market have been used for the treatment of erectile dysfunction but, at the same time, are in clinical trials investigating other pathologies such as pulmonary arterial hypertension, coronary vasospasm, benign prostatic hyperplasia etc. This review analyzes the PDE5 inhibitors currently in clinical use, the drugs in clinical trials and the most representative chemical classes published in literature in this last decade.

引用

页码：2564 / 2587

页数：24

共 185 条

[1]

Ahn S.K., 2008, PCT Patent, Patent No. [WO2008020711A1, 2008020711]

[2] A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability [J].

Allerton, Charlotte M. N. ;

Barber, Christopher G. ;

Beaumont, Kevin C. ;

Brown, David G. ;

Cole, Susan M. ;

Ellis, David ;

Lane, Charlotte A. L. ;

Maw, Graham N. ;

Mount, Natalie M. ;

Rawson, David J. ;

Robinson, Colin M. ;

Street, Stephen D. A. ;

Summerhill, Nicholas W. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (12) :3581-3594

[3]

ALLERTON CM, 2002, Patent No. 02079203

[4]

[Anonymous], [No title captured]

[5]

[Anonymous], [No title captured]

[6] Sildenafil citrate for the treatment of pulmonary arterial hypertension [J].

Antoniu, SA .

EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) :825-828

[7]

Antoniu SA, 2008, EXPERT OPIN INV DRUG, V17, P965, DOI [10.1517/13543784.17.6.965, 10.1517/13543784.17.6.965 ]

[8] Potent and selective xanthine-based inhibitors of phosphodiesterase 5 [J].

Arnold, Nichola J. ;

Arnold, Ruth ;

Beer, David ;

Bhalay, Gurdip ;

Collingwood, Stephen P. ;

Craig, Sarah ;

Devereux, Nicholas ;

Dodds, Mark ;

Dunstan, Andrew R. ;

Fairhurst, Robin A. ;

Farr, David ;

Fullerton, Joseph D. ;

Glen, Angela ;

Gomez, Sylvie ;

Haberthuer, Sandra ;

Hatto, Julia D. I. ;

Howes, Colin ;

Jones, Darryl ;

Keller, Thomas H. ;

Leuenberger, Beate ;

Moser, Heinz E. ;

Muller, Irene ;

Naef, Reto ;

Nicklin, Paul A. ;

Sandham, David A. ;

Turner, Katharine L. ;

Tweed, Morris F. ;

Watson, Simon J. ;

Zurini, Mauro .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (08) :2376-2379

[9] 8-aryl xanthines potent inhibitors of phosphodiesterase 5 [J].

Arnold, R ;

Beer, D ;

Bhalay, G ;

Baettig, U ;

Collingwood, SP ;

Craig, S ;

Devereux, N ;

Dunstan, A ;

Glen, A ;

Gomez, S ;

Haberthuer, S ;

Howe, T ;

Jelfs, S ;

Moser, H ;

Naef, R ;

Nicklin, P ;

Sandham, D ;

Stringer, R ;

Turner, K ;

Watson, S ;

Zurini, M .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) :2587-2590

[10] Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice [J].

Baratti, CM ;

Boccia, MM .

BEHAVIOURAL PHARMACOLOGY, 1999, 10 (08) :731-737

← 1 2 3 4 5 6 7 8 9 10 →